The Prevalence of Thrice, Twice, and Once Human Papillomavirus DNA Positivity in Older Chinese Women

Guomin Hu†, Jun Xu†, Ling Xu* and Longmei Jin*

† Department of Obstetrics and Gynecology, Minhang Hospital, Fudan University, Shanghai, China, Minhang District Maternal and Child Health Hospital, Shanghai, China

**Correspondence:** Ling Xu xlgynae@163.com
Longmei Jin longmeijin@126.com

† These authors have contributed equally to this work

**Keywords:** human papillomavirus (HPV), repeated HPV DNA detection, community population, older women, negative for intraepithelial lesion or malignancy (NILM)

**INTRODUCTION**

It has been established that persistent high-risk human papillomavirus (HR-HPV) infection is associated with high-grade cervical precancer (1–3). In theory, a persistent or transient infection caused by a given virus is determined primarily by the organ or cells it infects and the host's immune response. HPV infects basal proliferating keratinocytes but expresses high levels of viral proteins and replicates only in the upper layers of the stratum spinosum and granulosum of the
squamous epithelia (4, 5). Since keratinocytes undergo a specialized form of programmed cell death, cornification (6), the natural history of HPV infection should be influenced by the apoptosis of virus-laden keratinocytes (5). In addition, viral genome replication, viral protein expression, and virus assembly and release all occur only at the basal layer of the epithelium, which is an interface zone for the host's innate and adaptive immunity (3–5). These characteristics determine the particularity of the natural history of HPV infection. However, studies suggest that cell-mediated immunity is a main force that repels most HPV infections (3, 5), and the time required for clearance of the HR-HPV types (viral DNA can no longer be detected) averages 8–14 months (7–9).

HPV persistence is commonly defined as two or more viral DNA-positive time points (7–11). A recent meta-analysis showed that the average median duration of any HPV infection was 9.8 months (11), outlining that HR-HPV infection had a slightly longer median duration of 9.3 months than that of low-risk HPV (LR-HPV), which is 8.4 months (11). In terms of persistent duration, the top three HR-HPVs were HPV31, HPV33 and HPV16, with weighted averages of 14.4, 12.5, and 12.4 months, respectively (11). However, there is still no reasonable uniform definition of persistent infection in clinical practice, and current estimates of persistence vary greatly and differ by patient age, HPV genotype, detection method, treatment, and HPV testing interval (12).

Learning how long an HPV infection will persist has practical significance. Although persistent infection is theoretically determined primarily by the organ HPV infects and the host's immune response, the exact natural history of HPV infection is difficult to reveal owing to the lack of classic dynamic immune processes shown by a virus that causes viremia. Thus, repeated HPV DNA detection could promote the understanding of the duration of virus infection. Under this premise, a study focused on infection persistence is critical in determining the temporal correlation between a given HPV infection and the occurrence of cervical lesions. In addition, an accurate understanding of the duration of virus infection provides a theoretical basis for improving the ability to clear HPV infection by procedures such as loop excision, conization, and cryotherapy.

Beginning in 2014, a Pap smear and HPV cotesting program was implemented among older women living in the Minhang district of Shanghai. Among person-time data from 225,000 participants, 632 subjects had 3 repeated visits and at least one HPV DNA-positive result in the last 5 years. This report evaluates the proportions, age distribution, and cervical cytological examination of thrice, twice, and once HPV DNA-positive women.

**METHODS**

**Study Design and Participants**

This is a retrospective study focused on older women living in the Minhang district of Shanghai. As we reported previously (2), the Shanghai Minhang District Health and Family Planning Commission have implemented a community-based Pap smear and HPV cotesting screening program in the Minhang district, which has a population of 2.43 million in nine towns. Commencing in 2014, screening was implemented in four towns with more than 50,000 women screened annually, some of whom took part in multiple annual screenings from 2014 to 2019. In general, the interval of repeated visits is 12 months. The visit date, HPV results, and cytopathological results of these participants are recorded annually. The results outlined in this report involved participants who underwent cotesting 3 times and had ≥1 positive HPV DNA result for any HPV strain.

**Cytological Examinations**

As we reported previously (2), all cytological examination procedures strictly followed the 2014 Bethesda System for Reporting Cervical Cytology (13). Each cervical sample for cytological examination was taken using a sterile cytobrush inserted into the cervical os and rotated 360°. The cells were then evaluated as recommended by the manufacturer of the BD SurePath liquid-based Pap test (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). The results, cervicitis/no intraepithelial lesion or malignancy (NILM); atypical squamous cells—of undetermined significance (ASC-US); atypical squamous cells—cannot exclude high-grade squamous intraepithelial lesion (HSIL) (ASC-H); low-grade squamous intraepithelial lesion (LSIL); and HSIL, were reported using the Bethesda System for Reporting Cervical Cytology; Definitions, Criteria, and Explanatory Notes; Third Edition (13). Those with ASC-US and higher cytological grades underwent colposcopy and biopsy; four lesion-directed biopsy samples were obtained from distinct epithelial regions in the cervical transformation zone, which turned white upon application of 5% (v/v) acetic acid. All biopsies were ranked in order of lesion severity at the time of colposcopy and were evaluated by at least two certified pathologists blinded to the clinical data.

**HPV Genotyping**

As we reported previously (2), at the time of Pap testing, cervical specimens for HPV testing were collected using a sterile cytobrush as described above, and viral DNA was extracted using QIAamp DNA Mini Kits (QIAGEN, Shanghai, China). HPV DNA evaluation and genotyping were performed using a kit provided by Huada Biotech Co., Ltd. (Wuhan, China). The kit detects 12 HR-HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59), two possibly carcinogenic genotypes (66 and 68), and two LR-HPV strains (6 and 11). The kit employs polymerase chain reaction followed by HPV genotype-specific DNA microarray analysis. It has been approved by the Chinese Food and Drug Administration. All procedures followed the manufacturer's protocols.

**Statistical Analysis**

Because our participants had 1–3 results for a given variable, person-time was adopted in the statistical analysis. Continuous variables are presented as the means ± standard deviations, and categorical data are presented as frequencies with percentages. Differences between and within groups were evaluated using one-way ANOVA, t-test, chi-squared test, or Fisher's exact probability test, as appropriate. All statistical analyses were performed with
the aid of SPSS software (ver. 13.0; SPSS Inc., Chicago, IL, USA), and the significance level was set at $\alpha = 0.05$.

**RESULTS**

**A General Description of Participants**

A community-based screening program with Pap smear and HPV cotesting yielded 225,000 person-time data from 2014 to 2019. A total of 12,706 person-times had at least 1 positive test for any HPV DNA over the 5 years. Among these, 632 subjects with 1,020 person-time data were involved in this analysis (Figure 1). All HPV-negative subjects ($N = 23,196$) assembled in the first half of 2017 were adopted as “controls.” As shown in Table 1, the numbers of subjects with thrice, twice, and once positive results for a given HPV DNA were 269, 131, and 231, respectively. A total of 95.2% of HPV-infected women and 97.8% of HPV-free women showed cytological results of NILM (Table 1).

**Percentages of Thrice, Twice, and Once HPV DNA-Positive Person-Time Among Strains**

The person-times of thrice, twice, and once HPV DNA-positive tests for each strain were calculated. To determine the distribution of thrice, twice, and once HPV DNA-positive rates among strains, the above person-times were divided by total person-time (1,020) and plotted in order from high to low thrice and twice positive rates. As shown in Figure 2, HPV52 is the dominant strain with the highest percentages of total positive (20.3%), thrice positive (14.5%), twice positive (2.9%), and once positive tests (2.8%). HPV58 is the 2nd most dominant strain, and the percentages of total and thrice HPV DNA-positive tests were 15.3 and 12.2%, respectively.

To determine the distribution of thrice, twice, and once HPV DNA-positive rates within each strain, the above person-times were divided with the total person-time of each HPV strain and plotted in order from high to low of thrice positivity. As shown in Figure 3, the person-time of thrice HPV58, 35, 52, 56, 18, 68, 31, 16, 33, and 45 DNA-positive surpassed 50%. Together with the results of twice DNA positivity, the person-times of twice and thrice DNA positivity all exceeded 60%.

In this report the period duration (last test date – first test date) of thrice and twice HPV DNA positive tests ranged from 2 to 4 years. Since this study is not specially designed to determine the true duration of HPV infection and the time nodes are artificially controlled, we did not pursue further analysis of the period here.

**Age Difference Among and Within HPV Strains**

The average ages of women thrice, twice, and once positive for HPV DNA were calculated for each strain. One-way ANOVA showed that the average ages differed by strain in both thrice and twice HPV DNA-positive women. Figure 4 was plotted by the average ages from high to low of thrice HPV DNA-positive women. The average age for women with thrice HPV66 DNA-positive results was 64.2 ± 5.3 yo and declined to 49.4 ± 8.6 yo for HPV59. The oldest and youngest average ages for twice HPV DNA-positive women were 61.7 ± 6.2 yo (HPV35) and 52.3 ± 8.0 yo (HPV39). The average ages for HPV DNA-positive women ranged from 54.4 ± 7.8 yo (HPV39) to 61.5 ± 10.5 yo (HPV66) among strains (Figure 4).

The average age of HPV-free controls was 59.0 ± 7.2 yo, which was close to the median of the average ages for thrice and twice

---

**TABLE 1 | A general description of the subjects.**

|                | HPV infected | HPV free |
|----------------|--------------|----------|
| Number of subjects | 632          | 23,196   |
| Person-years     | 1020         | 23,196   |
| Age, yo          | 57.0 ± 6.8   | 59.0 ± 7.2 |
| Number of subjects thrice positive for one HPV strain | 269 (42.6%) | 0       |
| Number of subjects twice positive for one HPV strain | 132 (20.9%) | 0       |
| Number of subjects once positive for one HPV strain | 231 (36.6%) | 0       |
| NILM, person-years | 971 (95.2%) | 22,683 (97.8%) |
| LSIL, person-years | 2 (0.2%)     | 3 (0.01%)       |
| HSIL, person-years | 2 (0.2%)     | 0 (0.0%)       |
| ASC-US, person-years | 45 (4.4%)  | 509 (2.2%)       |
FIGURE 2 | The distribution of thrice, twice, and once HPV DNA positivity among strains. The person-time of each HPV strain was calculated thrice, twice, and once HPV DNA positivity. The percentage of above person-times was calculated by dividing the total person-time by 1,020 and plotted in order from high to low (thrice and twice positive).

FIGURE 3 | The distribution of thrice, twice, and once HPV DNA positivity within strains. The person-time of each HPV strain was calculated for thrice, twice, and once HPV DNA positivity. The percentage of above person-times was calculated by dividing the total person-time of each HPV strain and plotted in order from high to low for thrice DNA positivity.
HPV DNA-positive women and older than most of the average ages for once HPV-positive women (Figure 4).

For HPV66 and 39, the average ages of thrice positive women were significantly greater than those of twice positive women. For HPV66, 11, 16, and 51, the average ages of thrice positive women were significantly older than those of once positive women. For HPV18, 51, and 52, the average ages of twice positive women were significantly greater than those of once positive women. As an exception, for HPV59, the average ages of twice positive women were significantly greater than those of thrice positive women (Figure 4).

**Differences in NILM Distribution Among and Within Strains**

The percentages of NILM in women who were thrice, twice, and once positive for HPV DNA were calculated by strain. The percentage of women NILM among HPV-free women was 97.8%. For the thrice HPV DNA-positive women, Figure 5 shows the order from high to low according to the NILM percentages. The percentages for HPV11, 45, and 66 were 100% and declined to 83.3% for HPV59; the percentages for HPV52, 58, 16, 56, and 59 were significantly lower than the percentage of HPV-free women. Of twice HPV DNA-positive women, most HPV strain-infected women displayed 100% NILM, while the NILM percentages for twice HPV31 and 51 DNA-positive women were significantly lower than those for HPV-free women.

**DISCUSSION**

In this report, the distribution trends of thrice, twice, and once positivity for HPV DNA of 12 HR-HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59), two possibly carcinogenic genotypes (66 and 68), and two LR-HPV strains (6 and 11) were assessed in local older women. Our data shows that thrice and/or twice positivity for a given HPV DNA is highly prevalent in these subjects. For the total 1,020 person-time HPV infection, HPV52 and 58 were the top two strains, constituting 20.3 and 15.3% of person-time in total (thrice, twice, and once) and 14.5 and 12.2% of person-time for thrice positivity. When this trend was isolated by strain, thrice positive constitutions exceeded 50% for HPV58, 35, 52, 56, 18, 68, 31, 16, and 33; HPV58, 35, and 52 were the top three strains with >70% thrice positive ratios. The prevalence of once DNA positivity was relatively higher for the two LR-HPVs, 11 and 6. Regarding the age trend, the average age differed by strain in thrice, twice, or once HPV DNA-positive women. In general, the more positive test results women had, the older they were on average for HPV 66, 11, 16, 18, 51, 52, and 39. Although most HPV-infected and HPV-free women were NILM in cervical cytology, the percentages of women with thrice positivity for HPV52, 58, 16, 56, and 59 and women with twice positivity for HPV31 and 51 were significantly lower than the percentage in HPV-free controls.

Extrapolating from existing knowledge, once positivity for HPV DNA detected by a reliable approach, might mean a recent
The distribution of NILM. The percentages of NILM cervical cytology results for women with thrice, twice, and once positivity for HPV DNA were calculated by strain. The percentages were plotted in order from high to low according to the percentages of women with thrice HPV DNA-positive results.

Reports have shown that HPV52, 16, and 58 were the top three most dominant HR-HPV genotypes prevalent in local areas, with positivity rates of 23.0–23.9%, 17.7–18.0%, and 16.9–15.7%, respectively (2, 16, 17). Our data indicate not only the ratios for person-time in total, but also that the thrice positive person-time of HPV52, 58, and 16 are still in the top three. In addition, twice and once positive ratios of HPV52 are higher. The twice and once positive ratios of HPV16 and 58 were higher but surpassed by those of the other genotypes.

A key uncertainty in the natural history of HPV infection is whether an HPV infection that becomes undetectable on repeat testing has truly cleared or whether the virus persists at low, undetectable levels (18). While no answer to this question can be derived by current science and technology, studies suggest that redetection of the same HPV genotype occurs in at least 10–20% of women who have been observed to have “cleared” the virus (18, 19), and multiple studies have confirmed immunologically controlled redetection or reactivation of a previously acquired type-specific HPV infection (18, 20).

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the articlesupplementary material.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Review Board of the Ethics Committee of Medical Research at Minhang Hospital (Shanghai, China) approved the study protocol (Approval No. 2013SHMH004). The
patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

LX and LJ: conception and design of study, revising the manuscript critically for important intellectual content, and drafting the manuscript. GH and JX: analysis and/or interpretation of data. All authors: approval of the version of the manuscript to be published and acquisition of data.

**REFERENCES**

1. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens–part B: biological agents. *Lancet Oncol*. (2009) 4:321–2. doi: 10.1016/S1470-2045(09)70086-8

2. Xu J, Xia Z, Wang L, Yang R, Zhi Y, Zhu X, et al. Human papillomaviruses 16 and 58 are distributed widely among women living in Shanghai, China, with high-grade, squamous intraepithelial lesions. *Epidemiol Infect.* (2019) 147:e42. doi: 10.1017/S0950268818003011

3. Schiffman M, Castle PE, Jereonimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. *Lancet*. (2007) 370:980–907. doi: 10.1016/S0140-6736(07)61416-0

4. Stanley M. Immune responses to human papillomavirus. *Vaccine*. (2006) 24:S16–22. doi: 10.1016/j.vaccine.2005.09.002

5. Bian T, Wang Y, Lu Z, Ye Z, Zhao L, Ren J, et al. Human papillomavirus type 16 L1E7 chimeric capsomers have prophylactic and therapeutic efficacy against papillomavirus in mice. *Mol Cancer Ther.* (2008) 7:1329–35. doi: 10.1158/1535-7163.MCT-07-2015

6. Lippens S, Hoste E, Vandenabeele P, Agostinis P, Declercq W. Cell death in the skin. *Apoptosis*. (2009) 14:549–69. doi: 10.1007/s10495-009-0324-z

7. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. *J Infect Dis*. (1999) 180:1415–23. doi: 10.1086/315086

8. Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women’s Health Study. *J Infect Dis.* (2002) 186:462–9. doi: 10.1086/341782

9. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. *J Infect Dis.* (2005) 191:182–92. doi: 10.1086/426867

10. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. *JAMA*. (2001) 286:3106–14. doi: 10.1001/jama.286.24.3106

11. Rositch AF, Koshiol J, Hudgens MG, Razzagh H, Backes DM, Pimenta JM, et al. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. *Int J Cancer*. (2013) 133:1271–85. doi: 10.1002/ijc.27828

12. Hoffman SR, Le T, Lockhart A, Sanusi A, Dal Santo L, Davis M, et al. Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): a systematic review. *Int J Cancer*. (2017) 141:8–23. doi: 10.1002/ijc.30623

13. Nayar R, Wilbur D. The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes. New York, NY: Dordrecht; London: Springer Cham Heidelberg (2015). doi: 10.1001/jama.286.3.11074-5

14. Sawaya GF, McConnell KJ, Kulasingam SL, Lawson HW, Kerlikowske K, Melnikow J, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. *N Engl J Med*. (2003) 349:1501–9. doi: 10.1056/NEJMoa035419

15. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. *J Infect Dis.* (2005) 191:1808–16. doi: 10.1086/428779

16. Gu Y, Yi M, Xu Y, Zhao H, Fu F, Zhang Y. Genotype distribution characteristics of high-risk human papillomaviruses in women from Shanghai, China. *Epidemiol Infect.* (2016) 144:1482–9. doi: 10.1017/S0950268815002721

17. Gu Y, Ma C, Zou J, Zhu Y, Yang R, Xu Y, et al. Prevalence characteristics of high-risk human papillomaviruses in women living in Shanghai with cervical precancerous lesions and cancer. *Oncotarget*. (2016) 7:24656–63. doi: 10.18632/oncotarget.8262

18. Gravitt PE, Winer RL. Natural history of HPV infection across the lifespan: role of viral latency. *Viruses*. (2017) 9:E267. doi: 10.3390/v9100267

19. Gravitt PE. Evidence and impact of human papillomavirus latency. *Open Virol J*. (2012) 6:198–203. doi: 10.2174/1874357901206010198

20. Fu TC, Carter JJ, Hughes JP, Feng Q, Hawes SE, Schwartz SM, et al. Redetection vs. new acquisition of high-risk human papillomavirus in mid-adult women. *Int J Cancer*. (2016) 139:2201–12. doi: 10.1002/ijc.30283

**FUNDING**

This study was supported by a grant of the Shanghai Municipal Commission of Health and Family Planning (Serial No. 201840340); and Wu Jieping research fund (Serial No. 320.6750.13152).

**ACKNOWLEDGMENTS**

The authors thank the participants for supporting our report.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Hu, Xu, Xu and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.